Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04638309 · ClinicalTrials.gov registry record · Phase 1
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
A Phase 1 study, sponsored by Aprea Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04638309 is a Phase 1 study that was terminated before completion, run by Aprea Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT04638309, a Phase 1 study, was terminated before completion, sponsored by Aprea Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Phase 1 study evaluating the safety and efficacy of APR-548 in combination with Azacitidine for the treatment of TP53-Mutant Myelodysplastic Syndromes.
Interventions
- DRUG APR-548 + Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2022-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04638309
The ClinicalTrials.gov registry entry for NCT04638309 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aprea Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which APR-548 + Azacitidine is the first listed.
NCT04638309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04638309 about?
NCT04638309 is a clinical study titled "APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)". Phase 1 study evaluating the safety and efficacy of APR-548 in combination with Azacitidine for the treatment of TP53-Mutant Myelodysplastic Syndromes.
What is the current status of trial NCT04638309?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-09-20. Estimated completion is 2022-04-25.
What interventions are being tested in trial NCT04638309?
The interventions under investigation include: APR-548 + Azacitidine (DRUG).
Who is sponsoring clinical trial NCT04638309?
This trial is sponsored by Aprea Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.